Mitochondrial mitophagic mechanisms of myocardial matrix metabolism and remodelling

Archives of Physiology and Biochemistry

Volumn 118, Issue 1, 2012, Pages 31-42

  Vacek, Thomas P ^a   Vacek, Jonathan C ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Ca 2+; Homocysteine; Matrix metalloproteinases; NMDA receptor; Oxidative stress

Indexed keywords

CALCIUM; HOMOCYSTEINE; MATRIX METALLOPROTEINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLASMIN; PLASMINOGEN; REACTIVE OXYGEN METABOLITE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CALCIUM EXCHANGER 1; SODIUM-CALCIUM EXCHANGER 1;

ANIMAL; AUTOPHAGY; ENZYMOLOGY; EXTRACELLULAR MATRIX; HEART MITOCHONDRION; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HUMAN; HYPERHOMOCYSTEINEMIA; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOLOGY; PERMEABILITY; REVIEW;

ANIMALS; AUTOPHAGY; CALCIUM; EXTRACELLULAR MATRIX; FIBRINOLYSIN; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MATRIX METALLOPROTEINASES; MICE; MITOCHONDRIA, HEART; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PERMEABILITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PLASMINOGEN; REACTIVE OXYGEN SPECIES; RECEPTORS, N-METHYL-D-ASPARTATE; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SODIUM-CALCIUM EXCHANGER; VENTRICULAR REMODELING;

EID: 84856597398     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2011.635660     Document Type: Review

References (163)

1. Andreasen PA, Kjoller L, Christensen L, Dufy MJ. (1997). Te urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72(1):1-22. (Pubitemid 27314632)
2. Archer SL. (2010). Te mitochondrion as a Swiss army knife: implications for cardiovascular disease. J Mol Med (Berl) 88(10):963-5.
3. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Tomas JD, Topol EJ, Hazen SL, Penn MS. (2003). Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 197(5):615-24. (Pubitemid 36314656)
4. Becker A, Smulders YM, van GC, Stehouwer CD. (2003). Epidemiology of homocysteine as a risk factor in diabetes. Metab Syndr Relat Disord 1(2):105-20.
5. Bendeck MP, Irvin C, Reidy MA. (1996). Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 78(1):38-43. (Pubitemid 26004118)
6. Berman RS, Martin W. (1993). Arterial endothelial barrier dysfunction: actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. Br J Pharmacol 108(4):920-26. (Pubitemid 23102209)
7. Beyer EC, Kistler J, Paul DL, Goodenough DA. (1989). Antisera directed against connexin43 peptides react with a 43-k D protein localized to gap junctions in myocardium and other tissues. J Cell Biol 108(2):595-605. (Pubitemid 19065855)
8. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. (2006). Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354(15):1578-88.
9. Brady AJ, Warren B., Poole-Wilson PA, Williams TJ, Harding SE. (1993). Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 265(1 Pt 2) H176-82. (Pubitemid 23224707)
10. Brand MD, Afourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL, Parker N. (2004). Mitochondrial superoxide: production, biological efects, and activation of uncoupling proteins. Free Radic Biol Med 37(6):755-67. (Pubitemid 39078548)
11. Brude IR, Finstad HS, Seljefot I, Drevon CA, Solvoll K, Sandstad B, Hjermann I, Arnesen H, Nenseter MS. (1999). Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers. Eur J Clin Invest 29(2):100-8. (Pubitemid 29090248)
12. Cai B, Shan L, Gong D, Pan Z, Ai J, Xu C, Lu Y, Yang B. (2009). Homocysteine modulates sodium channel currents in human atrial myocytes. Toxicology 256(3):201-6.
13. Carmeliet P, Bouche A, De CC, Janssen S, Pollefeyt S, Wyns S, Mulligan RC, Collen D. (1995). Biological efects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 748:367-81.
14. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. (1997). Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 96(9):3180-91. (Pubitemid 27500124)
15. Cho A, Reidy MA. (2002). Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 91(9):845-51. (Pubitemid 35285083)
16. Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. (1990). Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 67(1):61-7. (Pubitemid 20223727)
17. Colucci WS, Alexander RW, Williams GH, Rude RE, Holman BL, Konstam MA, Wynne J, Mudge GH Jr, Braunwald E. (1981). Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med 305(4):185-90. (Pubitemid 11040736)
18. Coppen SR, Dupont E, Rothery S, Severs NJ. (1998). Connexin45 expression is preferentially associated with the ventricular conduction system in mouse and rat heart. Circ Res 82(2):232-43. (Pubitemid 28080106)
19. Cullen JP, Nicholl SM, Sayeed S, Sitzmann JV, Okada SS, Cahill PA, Redmond EM. (2004). Plasminogen activator inhibitor-1 defciency enhances fow-induced smooth muscle cell migration. Tromb Res 114(1):57-65. (Pubitemid 38942977)
20. D'Amico M, Di FC, Rossi F, Rossi F. (1999). Arrhythmias induced by myocardial ischaemia-reperfusion are sensitive to ionotropic excitatory amino acid receptor antagonists. Eur J Pharmacol 366(2-3):167-74. (Pubitemid 29080780)
21. Dalton TP, Shertzer HG, Puga A. (1999). Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol 39: 67-101. (Pubitemid 29222552)
22. de Smet BJ, de KD, Hanemaaijer R, Verheijen JH, Robertus L, van Der Helm YJ, Borst C, Post MJ. (2000). Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation 101(25):2962-7. (Pubitemid 30415888)
23. Dhamija RK, Gaba P, Arora S, Kaintura A, Kumar M, Bhattacharjee J. (2009). Homocysteine and lipoprotein (a) correlation in ischemic stroke patients. J Neurol Sci 281(1-2):64-8.
24. Dollery CM, Mc Ewan JR, Henney AM. (1995). Matrix metalloproteinases and cardiovascular disease. Circ Res 77(5):863-8.
25. Du C, Fang M, Li Y, Li L, Wang X. (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102(1):33-42.
26. Faccio L, Fusco C, Chen A, Martinotti S, Bonventre JV, Zervos AS. (2000). Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease Htr A and is regulated by kidney ischemia. J Biol Chem 275(4):2581-8. (Pubitemid 30082024)
27. Fedak PW, Altamentova SM, Weisel RD, Nili N, Ohno N, Verma S, Lee TY, Kiani C, Mickle DA, Strauss BH, Li RK. (2003). Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol 284(2):H626-34. (Pubitemid 36142891)
28. Ferlazzo N, Condello S, Curro M, Parisi G, Ientile R, Caccamo D. (2008). NF-kappa B activation is associated with homocysteine- induced injury in Neuro2a cells. BMC Neurosci 9:62.
29. Folbergrova J. (1994). NMDA and not non-NMDA receptor antagonists are protective against seizures induced by homocysteine in neonatal rats. Exp Neurol 130(2):344-50.
30. Fu X, Kassim SY, Parks WC, Heinecke JW. (2001). Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276(44):41279-87.
31. Gao X, Xu X, Pang J, Zhang C, Ding JM, Peng X, Liu Y, Cao JM. (2007). NMDA receptor activation induces mitochondrial dysfunction, oxidative stress and apoptosis in cultured neonatal rat cardiomyocytes. Physiol Res 56(5):559-69.
32. Gillespie W, Tyagi N, Tyagi SC. (2011). Role of PPARgamma, a nuclear hormone receptor in neuroprotection. Indian J Biochem Biophys 48(2):73-81.
33. Givvimani S, Qipshidze N, Tyagi N, Mishra PK, Sen U, Tyagi SC. (2011). Synergism between arrhythmia and hyperhomo-cysteinemia in structural heart disease. Int J Physiol Pathophysiol Pharmacol 3(2):107-19.
34. Gottlieb E, Armour SM, Harris MH, Tompson CB. (2003). Mitochondrial membrane potential regulates matrix confguration and cytochrome c release during apoptosis. Cell Death Difer 10(6):709-17. (Pubitemid 36675732)
35. Gray CW et al. (2000). Characterization of human Htr A2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem 267(18):5699-710.
36. Gros D, Dupays L, Alcolea S, Meysen S, Miquerol L, Teveniau-Ruissy, M. (2004). Genetically modifed mice: tools to decode the functions of connexins in the heart - new models for cardiovascular research. Cardiovasc Res 62(2):299-308. (Pubitemid 38496543)
37. Gros DB, Jongsma HJ. (1996). Connexins in mammalian heart function. Bioessays 18(9):719-730. (Pubitemid 26351964)
38. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. (2011). Regulation of matrix metalloproteinase activity in health and disease. FEBS J 278(1):28-45.
39. Hansson Petersen CA et al. (2008). Te amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA 105(35):13145-50.
40. Hasenstab D, Lea H, Clowes AW. (2000). Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening. Arterioscler Tromb Vasc Biol 20(3):853-9. (Pubitemid 30151703)
41. Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, Simon RH, Drew AF. (2000). Bleomycin-induced pulmonary fbrosis in fbrinogen-null mice. J Clin Invest 106(11):1341-50.
42. Heistad DD, Lopez JA, Baumbach GL. (1991). Hemodynamic determinants of vascular changes in hypertension and atherosclerosis. Hypertension 17(4 Suppl) 1117-11.
43. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, Collen D, Carmeliet P, Moons L. (2005). Loss or inhibition of u PA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166(1):15-25. (Pubitemid 40051656)
44. Hofmann MA et al. (1997). Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 20(12):1880-86.
45. Hofmann MA et al. (2001). Hyperhomocysteinemia enhances vascular infammation and accelerates atherosclerosis in a murine model. J Clin Invest 107(6):675-83.
46. Huang CF, Su MJ. (1999). Positive inotropic action of NMDA receptor antagonist (+)-MK801 in rat heart. J Biomed Sci 6(6):387-98.
47. Huijberts MS, Becker A, Stehouwer CD. (2005). Homocysteine and vascular disease in diabetes: a double hit? Clin Chem Lab Med 43(10):993-1000. (Pubitemid 41581950)
48. Hunt MJ, Aru GM, Hayden MR, Moore CK, Hoit BD, Tyagi SC. (2002). Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol 283(2):L239-45. (Pubitemid 34803979)
49. Hunt MJ, Tyagi SC. (2002). Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. Am J Physiol Cell Physiol 283(4):C1073-9.
50. Iimoto DS, Covell JW, Harper E. (1988). Increase in cross-linking of type I and type III collagens associated with volume-overload hypertrophy. Circ Res 63(2):399-408.
51. Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, Komoda T, Katayama S. (2001). Te ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50(1):3-11. (Pubitemid 32058541)
52. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S. (2000). Lipophilic HMG-Co A reductase inhibitor has an anti-infammatory efect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67(8):863-76. (Pubitemid 30491080)
53. Inoue I, Noji S, Awata T, Takahashi K, Nakajima T, Sonoda M, Komoda T, Katayama S. (1998). Bezafbrate has an antioxidant efect: peroxisome proliferator-activated receptor alpha is associated with Cu2+, Zn2+-superoxide dismutase in the liver. Life Sci., 63: (2) 135-144 available from: PM:9674948 (Pubitemid 28298667)
54. Jalil JE, Doering CW, Janicki JS, Pick R, Shrof SG, Weber KT. (1989). Fibrillar collagen and myocardial stifness in the intact hypertrophied rat left ventricle. Circ Res 64(6):1041-50. (Pubitemid 19155774)
55. Jiang F, Zhang Y, Dusting GJ. (2011). NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev 63(1):218-42.
56. Kagaya S, Kitanaka C, Noguchi K, Mochizuki T, Sugiyama A, Asai A, Yasuhara N, Eguchi Y, Tsujimoto Y, Kuchino Y. (1997). A functional role for death proteases in s-Myc- and c-Myc-mediated apoptosis. Mol Cell Biol 17(11):6736-45. (Pubitemid 27451221)
57. Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW. (1996). Te role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Tromb Vasc Biol 16(11):1373-82. (Pubitemid 26378228)
58. Krainc D, Bai G, Okamoto S, Carles M, Kusiak JW, Brent RN, Lipton SA. (1998). Synergistic activation of the N-methyl-D-aspartate receptor subunit 1 promoter by myocyte enhancer factor 2C and Sp1. J Biol Chem 273(40):26218-24. (Pubitemid 28475860)
59. Kreuzberg MM, Schrickel JW, Ghanem A, Kim JS, Degen J, Janssen-Bienhold U, Lewalter T, Tiemann K, Willecke K. (2006). Connexin30.2 containing gap junction channels decelerate impulse propagation through the atrioventricular node. Proc Natl Acad Sci USA 103(15):5959-64.
60. Kroemer G, Reed JC. (2000). Mitochondrial control of cell death. Nat Med 6(5):513-19. (Pubitemid 30305900)
61. Kruger O, Plum A, Kim JS, Winterhager E, Maxeiner S, Hallas G, Kirchhof S, Traub O, Lamers WH, Willecke K. (2000). Defective vascular development in connexin 45-defcient mice. Development 127(19):4179-93.
62. Kubota T, Mc Tiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM. (1997). Dilated cardiomyopathy in transgenic mice with cardiac-specifc overexpression of tumor necrosis factor-alpha. Circ Res 81(4) 627-35. (Pubitemid 27432751)
63. Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, Sung M, Sawicka J, Sims DE, Sawicki G, Schulz R. (2004). Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 18(6):690-92.
64. Lee TI, Kao YH, Chen YC, Pan NH, Lin YK, Chen YJ. (2011). Cardiac peroxisome-proliferator-activated receptor expression in hypertension co-existing with diabetes. Clin Sci (Lond) 121 (7):305-12.
65. Li LY, Luo X, Wang X. (2001). Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412(6842):95-99. (Pubitemid 32851517)
66. Li X, Simard JM. (1999). Multiple connexins form gap junction channels in rat basilar artery smooth muscle cells. Circ Res 84(11): 1277-84. (Pubitemid 29270042)
67. Li YF, Cornish KG, Patel KP. (2003). Alteration of NMDA NR1 receptors within the paraventricular nucleus of hypothalamus in rats with heart failure. Circ Res 93(10):990-97. (Pubitemid 37433237)
68. Li YY, Feng YQ, Kadokami T, Mc Tiernan CF, Draviam R, Watkins SC, Feldman AM. (2000a). Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 97(23):12746-51.
69. Li YY, Kadokami T, Wang P, Mc Tiernan CF, Feldman AM. (2002). MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol 282(3):H983-9. (Pubitemid 34654937)
70. Li YY, Mc Tiernan CF, Feldman AM. (2000b). Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46(2):214-24. (Pubitemid 30204593)
71. Lijnen HR. (2001). Plasmin and matrix metalloproteinases in vascular remodeling. Tromb Haemost 86(1):324-333. (Pubitemid 32663963)
72. Limb GA, Matter K, Murphy G, Cambrey AD, Bishop PN, Morris GE, Khaw PT. (2005). Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol 166(5):1555-63. (Pubitemid 40586523)
73. Liu RM, Gaston Pravia KA. (2010). Oxidative stress and glutathione in TGF-beta-mediated fbrogenesis. Free Radic Biol Med 48(1):1-15.
74. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. (1996). Induction of apoptotic program in cell-free extracts: requirement for d ATP and cytochrome c. Cell 86(1):147-57. (Pubitemid 26256586)
75. Loscalzo J. (2006). Homocysteine trials-clear outcomes for complex reasons. N Engl J Med 354(15):1629-32.
76. Loskutof DJ, Quigley JP. (2000). PAI-1, fbrosis, and the elusive provisional fbrin matrix. J Clin Invest 106 (12):1441-3. (Pubitemid 32038581)
77. Malemud CJ. (2006). Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11:1696-701. (Pubitemid 43253387)
78. Mann DL, Taegtmeyer H. (2001). Dynamic regulation of the extracellular matrix after mechanical unloading of the failing human heart: recovering the missing link in left ventricular remodeling. Circulation 104(10):1089-91. (Pubitemid 32830387)
79. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. (1988). Stimulation of collagen synthesis in fbroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett 238(2):343-6.
80. Mariappan N, Elks CM, Sriramula S, Guggilam A, Liu Z, Borkhsenious O, Francis J. (2010). NF-kappa B-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res 85(3):473-83.
81. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. (1998). Macrophages in human atheroma contain PPARgamma: diferentiation- dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 153(1):17-23. (Pubitemid 28317502)
82. Maurer M, Burri S, de MS, Hullin R, Martinelli M, Mohacsi P, Hess OM. (2010). Plasma homocysteine and cardiovascular risk in heart failure with and without cardiorenal syndrome. Int J Cardiol 141(1):32-8.
83. Mc Cawley LJ, Matrisian LM. (2001). Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 13(5):534-40. (Pubitemid 32817010)
84. Mc Elmurray III JH et al. (1999). Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative efects on left ventricular function and geometry. J Pharmacol Exp Ter 291(2):799-811.
85. Mc Gregor D, Shand B, Lynn K. (2000). A controlled trial of the efect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. Nephron 85(3):215-20. (Pubitemid 30429325)
86. Milani RV, Lavie CJ. (2008). Homocysteine: the Rubik's cube of cardiovascular risk factors. Mayo Clin Proc 83(11):1200-202.
87. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB. (1996). Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 94(1):35-43. (Pubitemid 126426397)
88. Miquerol L, Meysen S, Mangoni M, Bois P, van Rijen HV, Abran P, Jongsma H, Nargeot J, Gros D. (2004). Architectural and functional asymmetry of the His-Purkinje system of the murine heart. Cardiovasc Res 63(1):77-86. (Pubitemid 38759812)
89. Mondy JS, Williams JK, Adams MR, Dean RH, Geary RL. (1997). Structural determinants of lumen narrowing after angioplasty in atherosclerotic nonhuman primates. J Vasc Surg 26(5): 875-83
90. Moshal KS, Kumar M, Tyagi N, Mishra PK, Metreveli N, Rodriguez WE, Tyagi SC. (2009). Restoration of contractility in hyperhomocysteinemia by cardiac-specifc deletion of NMDA-R1. Am J Physiol Heart Circ Physiol 296(3):H887-92.
91. Moshal KS, Metreveli N, Frank I, Tyagi SC. (2008a). Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. Curr Vasc Pharmacol 6(2):84-92.
92. Moshal KS, Rodriguez WE, Sen U, Tyagi SC. (2008b). Targeted deletion of MMP-9 attenuates myocardial contractile dysfunction in heart failure. Physiol Res 57(3):379-84.
93. Moshal KS, Singh M, Sen U, Rosenberger DS, Henderson B, Tyagi N, Zhang H, Tyagi SC. (2006). Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC Am J Physiol Heart Circ Physiol 291(6):H2825-35. (Pubitemid 44904083)
94. Moshal KS et al . (2008c). Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 295(2):H890-97.
95. Moshal KS, Tyagi N, Henderson B, Ovechkin AV, Tyagi SC. (2005). Protease-activated receptor and endothelial-myocyte uncoupling in chronic heart failure. Am J Physiol Heart Circ Physiol 288(6):H2770-77. (Pubitemid 40720657)
96. Mujumdar VS, Aru GM, Tyagi SC. (2001). Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem 82(3):491-500. (Pubitemid 32729412)
97. Mujumdar VS, Tummalapalli CM, Aru GM, Tyagi SC. (2002). Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR. Am J Physiol Cell Physiol 282(5):C1009-15. (Pubitemid 34663109)
98. Mukherjee D, Sen S. (1990). Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res 67(6):1474-80.
99. Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley III AJ, Spinale FG, Gold MR. (2006). Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fbrillation. Am J Cardiol 97(4):532-7. (Pubitemid 43190045)
100. Nasir K, Tsai M, Rosen BD, Fernandes V, Bluemke DA, Folsom AR, Lima JA. (2007). Elevated homocysteine is associated with reduced regional left ventricular function: the multi-ethnic study of atherosclerosis. Circulation 115(2):180-87. (Pubitemid 46105716)
101. Nelson KK, Melendez JA. (2004). Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 37(6):768-84. (Pubitemid 39078549)
102. Norton GR, Tsotetsi J, Trifunovic B, Hartford C, Candy GP, Woodiwiss AJ. (1997). Myocardial stifness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 96(6):1991-8. (Pubitemid 27400763)
103. Ntaios G et al. 2010. Te efect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial. Int J Cardiol 143(1):16-19.
104. Ow YP, Green DR, Hao Z, Mak TW. (2008). Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol 9(7):532-42. (Pubitemid 351881842)
105. Pavia C, Ferrer I, Valls C, Artuch R, Colome C, Vilaseca MA. (2000). Total homocysteine in patients with type 1 diabetes. Diabetes Care 23(1):84-87. (Pubitemid 30022900)
106. Pei D, Kang T, Qi H. (2000). Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J Biol Chem 275(43);33988-97.
107. Pinsky DJ, Patton S, Mesaros S, Brovkovych V Kubaszewski E, Grunfeld S, Malinski T. (1997). Mechanical transduction of nitric oxide synthesis in the beating heart. Circ Res 81(3):372-379. (Pubitemid 27362524)
108. Popp O, Heidinger M, Ruiz-Heinrich L, Ries C, Jochum M, Gil-Parrado S. (2003). Te calpastatin-derived calpain inhibitor CP1B reduces m RNA expression of matrix metalloproteinase-2 and -9 and invasion by leukemic THP-1 cells. Biol Chem 384(6);951-8. (Pubitemid 36874510)
109. Poynter ME, Daynes RA. (1998). Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappa B signaling, and reduces infammatory cytokine production in aging. J Biol Chem 273(49):32833-41. (Pubitemid 28557672)
110. Qureshi I et al. (2005). Homocysteine-induced vascular dysregulation is mediated by the NMDA receptor. Vasc Med 10(3);215-223. (Pubitemid 41479676)
111. Rackauskas M, Kreuzberg MM, Pranevicius M, Willecke K, Verselis VK, Bukauskas FF. (2007). Gating properties of heterotypic gap junction channels formed of connexins 40, 43, and 45. Biophys J 92(6):1952-65. (Pubitemid 46495259)
112. Ranganathan AC et al. 2001. Manganese superoxide dismutase signals matrix metalloproteinase expression via H2O2-dependent ERK1/2 activation. J Biol Chem 276(17):14264-14270.
113. Rassow J, Maarse AC, Krainer E, Kubrich M, Muller H, Meijer M, Craig EA, & Pfanner, N. 1994. Mitochondrial protein import: biochemical and genetic evidence for interaction of matrix hsp70 and the inner membrane protein MIM44. J Cell Biol 127(6 Pt 1):1547-556. (Pubitemid 24380895)
114. Reaume AG, de Sousa PA, Kulkarni S, Langille BL, Zhu D, Davies TC, Juneja SC, Kidder GM, Rossant J. (1995). Cardiac malformation in neonatal mice lacking connexin43. Science 267(5205):1831-4.
115. Robillon JF, Canivet B, Candito M, Sadoul JL, Jullien D, Morand P, Chambon P, Freychet P. (1994). Type 1 diabetes mellitus and homocyst(e)ine. Diabete Metab 20(5):494-6.
116. Rodriguez WE, Tyagi N, Deng AY, Adeagbo A, Joshua IG, Tyagi SC. (2008). Congenic expression of tissue inhibitor of metalloproteinase in Dahl-salt sensitive hypertensive rats is associated with reduced LV hypertrophy. Arch Physiol Biochem 114(5):340-348.
117. Ross R. (1993). Te pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362(6423):801-9.
118. Ruan L, Chen W, Srinivasan SR, Xu J, Sun M, Toprak A, Berenson GS. (2009). Relation of plasma homocysteine to arterial stifness in black and white young adults (from the Bogalusa Heart Study). Am J Cardiol 103(7):985-8.
119. Rucklidge GJ, Milne G, Mc Gaw BA, Milne E, Robins SP. (1992). Turnover rates of diferent collagen types measured by isotope ratio mass spectrometry. Biochim Biophys Acta 1156(1):57-61. (Pubitemid 23004905)
120. Saari H, Sorsa T, Lindy O, Suomalainen K, Halinen S, Konttinen YT. (1992). Reactive oxygen species as regulators of human neutrophil and fbroblast interstitial collagenases. Int J Tissue React 14(3):113-20.
121. Schmalfeldt B et al . (2001). Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7(8):2396-404. (Pubitemid 32751641)
122. Schulz R. 2007. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 47:211-242.
123. Schulz R, Heusch G. (2006). Connexin43 and ischemic preconditioning. Adv Cardiol 42:213-27. (Pubitemid 43805866)
124. Schwartz SM. (1997). Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 100(11 Suppl):S87-9. (Pubitemid 28009553)
125. Si-Tayeb K, Monvoisin A, Mazzocco C, Lepreux S, Decossas M, Cubel G, Taras D, Blanc JF, Robinson DR, Rosenbaum J. (2006). Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol 169(4):1390-1401. (Pubitemid 351194372)
126. Singh K, Communal C, Sawyer DB., Colucci WS. (2000). Adrenergic regulation of myocardial apoptosis. Cardiovasc Res 45(3):713-19. (Pubitemid 30047138)
127. Soinio, M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. (2004). Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 140(2):94-100.
128. Sood HS, Cox MJ, Tyagi SC. (2002). Generation of nitrotyrosine precedes activation of metalloproteinase in myocardium of hyperhomocysteinemic rats. Antioxid Redox Signal 4(5):799-804. (Pubitemid 35246943)
129. Spiess C, Beil A, Ehrmann M. (1999). A temperature-dependent switch from chaperone to protease in a widely conserved heat shock protein. Cell 97(3):339-47. (Pubitemid 29214590)
130. Susin SA et al . (1999). Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397(6718):441-6.
131. Takenouchi Y, Kobayashi T, Taguchi K, Matsumoto T, Kamata K. (2010). Relationship among superoxide-related enzyme, PPARs, and endothelium-dependent relaxation in murine aortas previously organ-cultured in high-glucose conditions. Can J Physiol Pharmacol 88(7):760-69.
132. Takeshita K et al. (2004). Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fbrosis after myocardial infarction. Am J Pathol 164(2):449-56. (Pubitemid 38364661)
133. Tamaddon HS, Vaidya D, Simon AM, Paul DL, Jalife J, Morley GE. (2000). High-resolution optical mapping of the right bundle branch in connexin40 knockout mice reveals slow conduction in the specialized conduction system. Circ Res 87(10):929-36.
134. Tanaka F, Ogura N, Abiko Y. (1997). Stimulation of plasminogen activator/plasmin system in gingival fbroblast cells by oxygen radicals. Arch Oral Biol 42(4):263-270. (Pubitemid 27270845)
135. Tarkun I, Cetinarslan B, Canturk Z, Tarkun P, Agacdiken A, Komsuoglu B. (2004). Homocysteine concentrations in type 2 diabetic patients with silent myocardial ischemia: a predictive marker. J Diabetes Complications 18(3):165-8. (Pubitemid 38622545)
136. Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ. (2009). Relationships of HDL cholesterol, Apo A-I, and Apo A-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofbrate. Arterioscler Tromb Vasc Biol 29(6):950-955.
137. Tikhomirov O, Carpenter G. (2005). Bax activation and translocation to mitochondria mediate EGF-induced programmed cell death. J Cell Sci 118(Pt 24):5681-90. (Pubitemid 43079262)
138. Touyz RM, Yao G, Viel E, Amiri F, Schifrin EL. (2004). Angiotensin II and endothelin-1 regulate MAP kinases through diferent redox- dependent mechanisms in human vascular smooth muscle cells. J Hypertens 22(6):1141-9. (Pubitemid 38721006)
139. Tummalapalli CM, Tyagi SC. (1999). Responses of vascular smooth muscle cell to extracellular matrix degradation. J Cell Biochem 75(3):515-27. (Pubitemid 29521658)
140. Turrens JF. (2003). Mitochondrial formation of reactive oxygen species. J Physiol 552(Pt 2):335-44. (Pubitemid 37321833)
141. Tyagi N., Vacek JC, Givvimani S, Sen U, Tyagi SC. (2010). Cardiac specifc deletion of N-methyl-d-aspartate receptor 1 ameliorates mt MMP-9 mediated autophagy/mitophagy in hyperhomocysteinemia. J Recept Signal Transduct Res 30(2):78-87.
142. Tyagi SC. (1999). Homocyst(e)ine and heart disease: patho- physiology of extracellular matrix. Clin Exp Hypertens 21(3): 181-98. (Pubitemid 29193632)
143. van Rijen HV, Eckardt D, Degen J, Teis M, Ott T, Willecke K, Jongsma HJ, Opthof T, de Bakker JM. (2004). Slow conduction and enhanced anisotropy increase the propensity for ventricular tachyarrhythmias in adult mice with induced deletion of connexin43. Circulation 109(8):1048-55. (Pubitemid 38282860)
144. van Rijen HV, van Veen TA, van Kempen MJ, Wilms-Schopman FJ, Potse M, Krueger O, Willecke K, Opthof T, Jongsma HJ, de Bakker JM. (2001). Impaired conduction in the bundle branches of mouse hearts lacking the gap junction protein connexin40. Circulation 103(11):1591-8. (Pubitemid 32226270)
145. Van LG et al . 2002a. A matrix-assisted laser desorption ionization post-source decay (MALDI-PSD) analysis of proteins released from isolated liver mitochondria treated with recombinant truncated Bid. Cell Death Difer 9(3);301-8.
146. Van LG et al. (2001). Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Difer 8(12):1136-42.
147. Van LG, Van GM, Depuydt B, Srinivasula SM, Rodriguez I, Alnemri ES, Gevaert K, Vandekerckhove, J, Declercq W, Vandenabeele P. (2002b). Te serine protease Omi/Htr A2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Difer 9(1):20-26. (Pubitemid 34071990)
148. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL. (2000). Identifcation of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102(1): 43-53.
149. Verheijck EE, van Kempen MJ, Veereschild M, Lurvink J, Jongsma HJ, Bouman LN. (2001). Electrophysiological features of the mouse sinoatrial node in relation to connexin distribution. Cardiovasc Res 52(1):40-50. (Pubitemid 32835237)
150. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. (2002). Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106(12):1543-9.
151. Weber KT, Brilla CG, Campbell SE, Zhou, G, Matsubara L, Guarda E. (1992). Pathologic hypertrophy with fbrosis: the structural basis for myocardial failure. Blood Press 1(2):75-85.
152. Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP. (1989). Patterns of myocardial fbrosis. J Mol Cell Cardiol 21(Suppl 5): 121-131.
153. Wijekoon EP, Brosnan ME, Brosnan JT. (2007). Homocysteine metabolism in diabetes. Biochem Soc Trans 35(Pt 5): 1175-9. (Pubitemid 350206455)
154. Wilcken DE, Wilcken B. (1976). Te pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 57(4):1079-82.
155. Wilson E, Mai Q, Sudhir K, Weiss RH, Ives HE. (1993). Mechanical strain induces growth of vascular smooth muscle cells via autocrine action of PDGF. J Cell Biol 123(3):741-7. (Pubitemid 23324929)
156. Wright SC, Schellenberger U, Wang H, Kinder DH, Talhouk JW, Larrick JW. (1997). Activation of CPP32-like proteases is not sufcient to trigger apoptosis: inhibition of apoptosis by agents that suppress activation of AP24, but not CPP32-like activity. J Exp Med 186(7):1107-17. (Pubitemid 27441154)
157. Xi Q, Cheranov SY, Jaggar JH. (2005). Mitochondria-derived reactive oxygen species dilate cerebral arteries by activating Ca2+ sparks. Circ Res 97(4):354-62. (Pubitemid 41216140)
158. Xin X, Yang S, Kowalski J, Gerritsen ME. (1999). Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274(13): 9116-21. (Pubitemid 29164719)
159. Zhang HJ, Zhao W, Venkataraman S, Robbins ME, Buettner GR, Kregel KC, Oberley LW. (2002). Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species. J Biol Chem 277(23):20919-26. (Pubitemid 34967401)
160. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. (2000). Efects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 279(4):F671-8.
161. Zhou HZ, Ma X, Gray MO, Zhu BQ, Nguyen AP, Baker AJ, Simonis U, Cecchini G, Lovett DH, Karliner JS. (2007). Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun 358(1):189-95. (Pubitemid 46719101)
162. Zhou J, Austin RC. (2009). Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms. Biofactors 35(2):120-129.
163. Zhou J, Moller J, Danielsen CC, Bentzon J, Ravn HB, Austin RC, Falk E. (2001). Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in Apo E-defcient mice. Arterioscler Tromb Vasc Biol 21(9):1470-76. (Pubitemid 34219810)